Cheap antioxidant could replace costly drugs for Post-Transplant blood disorder
NCT ID NCT07279610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether N-acetylcysteine (NAC), a common antioxidant, can treat a severe blood vessel condition called TA-TMA that can happen after a stem cell transplant. Current treatments are either ineffective or very expensive. The trial will enroll 44 adults diagnosed with TA-TMA and measure if NAC improves blood counts and organ function. If successful, NAC could offer a safe, affordable option for this life-threatening complication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, China